Navigation Links
Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
Date:7/24/2012

vir against all major HIV subtypes resistant to current therapies, which may allow activity against tenofovir-resistant viruses (e.g., K65R), and against HBV.  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.  CMX157 has completed a Phase 1 clinical trial in healthy volunteers, demonstrating a favorable safety, tolerability and drug distribution profile. 

About Chimerix
Led by an experienced antiviral drug development team, Chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health.  The company's proprietary lipid technology has given rise to two clinical stage compounds, CMX001 and CMX157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. 

Chimerix's lead compound, CMX001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded DNA (dsDNA) viruses including cytomegalovirus (CMV), adenovirus, BK virus, herpes simplex virus and variola (smallpox).  CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV and is in Phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (HSCT) recipients.  To date, more than 750 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols.  Antiviral activity from completed and ongoing studies, coupled with the lack of myelotoxicity and nephrotoxicity that are associated with currently available therapies, indicate that CMX001 has the potential to improve outcomes for stem cell and solid organ transplant recipients.  Chimerix has completed an End of Phase 2 meeting with the FDA for CMX001 and is
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society
2. Chimerixs Broad Spectrum Antiviral Therapeutic, CMX001, Demonstrates Potential To Mitigate BK Virus Associated End-Organ Disease In Clinical Study
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
5. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
6. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
7. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
8. H. D. Smith Signs Three Year Prime Vendor Agreement with PharmacyGPO Buying Group
9. Bacterin International Signs Its Third National GPO Contract with Novation
10. MusclePharm Signs Pro Baseball Rookie Phenom Bryce Harper As Sponsored Athlete
11. Masimo Signs Pronto-7™ Distribution Deal with Henry Schein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... MOUNTAIN VIEW, Calif., March 5, 2015  IRIDEX Corporation (Nasdaq: ... fourth quarter and year ended January 3, 2015.  ... 2014, a record for the Company and up 11% from ... were $42.8 million, also a record, up 12% from $38.3 ... fourth quarter was 50.1%, up from 48.6% in the fourth ...
(Date:3/5/2015)... Bayer HealthCare announced today that it has ... of the American Society of Clinical Oncology (ASCO) to ... designed to unlock vast quantities of information about the ... "Bayer is proud to join ASCO and the Conquer ... to help people whose lives have been affected by ...
(Date:3/5/2015)... , March 5, 2015   AMC ... management solutions recognized for improving the effectiveness and ... that Robert Anazagasty and Jared ... serve as Vice President, Strategic Client Development, and ... These additions support AMC Health,s commitment to accelerating ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3
... Particle Sciences Inc. (PSI), a leading pharmaceutical ... supplier of ethylene vinyl acetate (EVA) into pharmaceutical ... of drug-eluting devices.  Building on years of collaboration, ... working to provide Particle Sciences with preferred access ...
... IRIDEX Corporation (NASDAQ: IRIX ) today announced that it ... closes on Thursday, May 5, 2011.  In ... with the investment community at 5:00 p.m. Eastern Time ... to discuss the results of the quarter and other business developments. ...
Cached Medicine Technology:Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations 2Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations 3
(Date:3/5/2015)... A Bakersfield, Calif. state court jury returned a verdict ... plaintiff Coleen M. Perry a total of $5.7 million for ... mesh sling device, manufactured by Ethicon, Inc., a subsidiary of ... at Wagstaff & Cartmell in Kansas City, Mo., ... Rich Freese and Tim Goss of Freese & Goss ...
(Date:3/5/2015)... March 05, 2015 Central Nebraska Imaging ... practice including the brand’s new logo and optimized website. ... the practice’s modern approach to expert diagnostic imaging, centered ... and be built to be a resource for Nebraska ... With automated forms, communication and referral functionality, video content ...
(Date:3/5/2015)... CA (PRWEB) March 05, 2015 On ... titled “Butt Augmentation, Labiaplasty on the Rise, Plastic Surgeons ... by the American Society for Aesthetic Plastic Surgery ... . Both groups reported a year-over-year doubling of surgical ... the physicians quoted in the article, this increase can ...
(Date:3/5/2015)... At the 7th Annual Mississippi ... addiction treatment met today in Jackson, Mississippi to listen ... Among the numerous respected speakers will be William ... role that pain medications have had in today’s opiate ... , "It is hard to believe that much of ...
(Date:3/5/2015)... March 05, 2015 University of ... founded in 1904, has launched a new center ... lifestyle changes. The Northwest Center for Lifestyle and ... support community outreach, and conduct research in the ... diet and nutrition. The center will target efforts ...
Breaking Medicine News(10 mins):Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2
... Prostatitis is a common,problem, yet the antibiotics physicians ... associated with this condition work in only a ... condition have a form called,chronic nonbacterial prostatitis, which ... edition of Harvard Medical School,s Perspectives on Prostate,Disease ...
... psychiatric nurses believe that people with Borderline Personality Disorder (BPD) ... adults suffer from the condition, according to the October issue ... Ninety-eight per cent of nurses said service shortages played a ... disagreements between staff on how to care for people with ...
... York, NYHealth insurance reform plans that build on a ... are shared among government, employers, and enrollees would have ... and would be the most practical to implement according ... Fund Commission on a High Performance Health System. Commissioners ...
... ... By Dana Ullman, MPH Foreword by Dr. Peter Fisher ... There is a good reason that 11,American presidents, 7 popes, Charles Darwin, ... for,homeopathic treatment: homeopathy works! The majority of people in Western society ...
... PHOENIX, Oct. 17, 2007 Two Arizona-based philanthropic ... innovative initiative to develop personalized molecular diagnostics. The ... every persons unique physiological makeup is critical to ... the same time reducing medical costs. , ...
... Onco-genomic guided trial design may increase probability of tumor response ... and ... Inc.,(CTI) (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), ... first,patient to its complete phase Ib trial of brostallicin used ...
Cached Medicine News:Health News:Antibiotics May Not Help Men's Chronic Pelvic Pain: Harvard Doctors Discuss Alternatives 2Health News:Services for patients with BPD need to be improved say psychiatric nurses 2Health News:Services for patients with BPD need to be improved say psychiatric nurses 3Health News:New report: private/public insurance mix is most practical way to achieve universal coverage 2Health News:New report: private/public insurance mix is most practical way to achieve universal coverage 3Health News:New report: private/public insurance mix is most practical way to achieve universal coverage 4Health News:The Homeopathic Revolution 2Health News:The Homeopathic Revolution 3Health News:Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 2Health News:Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 3Health News:Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 2Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 3Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 4
... Eyes enzymatic cleaner is a ... removes stubborn deposits in as ... eyes enzymatic cleaner contains an ... irritating film on soft contact ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Titanium. Straight shafts with curved lower tip. Upper tip fits into positioning hole while lower jaw stabilizes the lens. Flat smooth handle with dull finish. Most popular size or model....
Medicine Products: